Positron emission tomography/integrated computed tomography (PET/CT) provides the most accurate imaging modality for preoperative lung cancer staging. However, the diagnostic accuracy of maximum standardized uptake value (SUV max ) for mediastinal (N2) lymph nodes (LN) is unclear. We compared SUV max , the ratio of LN to primary tumor SUV max (SUV n/t ), and SUV n/t multiplied by maximal tumor diameter (SUV index ) in terms of their abilities to predict mediastinal LN malignancy.
Introduction
Lymph node (LN) staging, especially preoperative mediastinal LN assessment, is an important assessment in lung cancer patients, with implications for prognosis as well as direct impacts on patient management. [1] Positron emission tomography/ integrated computed tomography (PET/CT) is considered as the best noninvasive staging modality in lung cancers, [2, 3] though the sensitivity and specificity of maximal standardized uptake values (SUV max ) to predict LN malignancy have varied between studies. The sensitivity and specificity of the most widely used cutoff SUV max of 2.5 were 40% to 97% and 60% to 96%, respectively. [2] [3] [4] [5] [6] [7] [8] The reasons for this wide range included the study of different patient populations, varying criteria for malignancy, and patient-, tumor-, and technique-specific factors. [9, 10] Three previous studies reported on the use of the ratio of LN SUV max to primary tumor SUV max (SUV n/t ), rather than SUV max , to predict mediastinal LN malignancy, with the aim of reducing the influence of tumor-and technique-specific factors on the diagnosis. [11] [12] [13] Although those studies determined SUV n/t to be a good predictor of mediastinal LN malignancy, the accuracies varied between studies, and tumor diameter, as an important indicator of LN metastasis, was not accounted for in the formula. Furthermore, most LNs in those studies were acquired by biopsy or mediastinoscopy, which is associated with a high potential false-negative rate. In Mattes et al's study, [13] biopsy LNs were not restricted to LNs that appeared malignant on imaging, but were sampled at the discretion of the clinician who performed the biopsy. A total of 77% (392/504) of LNs were obtained by mediastinoscopy or fine needle aspiration, suggesting that up to 77% of PET/CT-positive LNs were not matched to their pathological diagnosis. Mediastinoscopy or fine needle aspiration were used to obtain 21.3% of LNs in Iskender et al's report, but the equivalent rate is not mentioned in Cerfolio's report.
We evaluated the relative capacities of SUV n/t , SUV max , and also SUV n/t multiplied by maximal tumor diameter (SUV index ) to predict mediastinal LN malignancy using LNs obtained by systemic lymph node resection to reduce the potential falsenegative rate. We also evaluated the abilities of these parameters to predict LN malignancy among smokers and nonsmokers, respectively.
Methods

Ethics statement
This retrospective analysis was approved by the institutional review board of The Chinese People's Liberation Army (PLA) General Hospital. All data were extracted from the hospital medical database and were only used for academic research.
Study population
In this single-center retrospective study, we assessed 170 mediastinal LN stations from 73 patients who underwent fluorodeoxyglucose (FDG) PET/CT and thoracotomy with systemic LN resection between April 2008 and April 2016. A total of 895 consecutive patients underwent PET/CT because of suspicious lung cancer nodules at the Chinese PLA General Hospital, among whom 219 underwent surgery for highly suspected lung cancers. Patients were included if they had at least one detectable mediastinal LN on PET/CT with a LN SUV max of 2.0 to 7.0 and an SUV max value for suspicious primary lung cancer >2.0. The LN SUV max was defined by LN station rather than by single LN because it was difficult to distinguish which LN within the station was responsible for the SUV max . We also assumed that the LN with the maximal SUV max on PET/CT in each station was most likely to be the malignant one. All PET/CTpositive LN stations underwent systemic LN dissection.
Patients with a tumor history or who underwent chemotherapy before PET/CT scan were excluded to avoid additional effects on SUV max . Patients with ground glass opacity (GGO) lung cancer, multiple primary lung cancers, and patients whose mediastinal LNs were obtained via thoracotomy LN sampling, mediastinoscopy, and fine needle aspiration were also excluded to reduce the incidence of potential false-negatives.
Pathological results were matched to the PET/CT findings by LN station. We initially analyzed 441 mediastinal LN stations from 219 patients who had undergone both thoracotomy with systemic LN resection and PET/CT examination. Seventeen patients were excluded because their lung nodules turned out to be benign. A further 42 patients were excluded because all their mediastinal LNs were silent at PET/CT, 68 patients were excluded for having SUV max <2.0 or >7.0, and 19 patients were excluded because of multiple primary lung cancers or GGO lung cancers.
PET/CT data collection and test methods
PET/CT scans were performed by using integrated PET/CT scanner (Siemens Biograph 64 High Definition). Patients were instructed to fast at least 6 hours before FDG administration. Whole body scans from the skull to feet (6 bed positions) were preformed 60 minutes later, after injection of 0.15 mCi/kg FDG. The CT examination performed for attenuation correction of PET images. Emission PET data were acquired for 2 minutes per bed position and iterative reconstruction with CT attenuation correction was performed. SUVmax of the primary and of each suspicious lymph node station was defined as the highest FDG uptake within a region of interest defined according to PERCIST criteria. [14] Primary tumor largest dimension, primary tumor SUVmax, and LNs SUVmax were measured at the same time. We define SUVn/t as LN SUVmax divided by primary tumor SUVmax; SUVindex was defined as SUVn/t multiply by primary tumor largest dimension.
Statistical methods
Patient, tumor, and LN characteristics were reported as descriptive statistics. SUV max , SUV n/t , and SUV index values were compared between pathologically positive and negative LNs using Mann-Whitney U tests. The areas under the curve (AUCs) for receiver-operating characteristic curves (ROC) were calculated for SUV max , SUV n/t , and SUV index to assess their abilities to predict LN malignancy, with an optimal cutoff value for each parameter for all LNs. The optimal cutoff value was defined as the point on the ROC curve with the maximum sum of sensitivity and specificity. AUCs of the ROC curves were also used to evaluate the abilities of SUV max , SUV n/t , and SUV index to predict malignancy in smokers and non-smokers, respectively. ROC curves were tested and compared using the Delong method.
Mann-Whitney U tests and ROC curves were tested and compared using Statistical Analysis System (SAS) version 9.4 (SAS Institute, Cary, NC). P values <0.05 were taken as significant.
Results
A total of 73 lung cancer patients (21 female, 52 male) with a mean age of 60.63 (median 60, range 36-81) years were included. Among all 73 patients, there were 170 PET/CT-positive mediastinal LN stations. All the LNs were confirmed pathology, with 28 malignant and 142 benign LN stations. The time interval between PET/CT and thoracotomy was 12.21 ± 5.56 (median 11, range 4-27) days. The tumor and patient characteristics are listed in Table 1 and the LN characteristics are listed in Table 2 .
According to the ROC curves, SUV index (AUC = 0.71, P < 0.001) was more accurate in predicting LN malignancy than SUV max (AUC = 0.67, P < 0.001) and SUV n/t (AUC = 0.59, P = 0.09) among all LNs (Fig. 1) . The difference between SUV index and SUV n/t was statistically significant (P = 0.0245), but that between SUV index and SUV max was not significant (P = 0.60).
We also evaluated the diagnostic utilities of SUV max , SUV n/t , and SUV index as predictors of LN malignancy among nonsmokers and smokers separately. SUV index (AUC = 0.72, P < 0.001) was more accurate in predicting malignancy than SUV max (AUC = 0.69, P < 0.001) and SUV n/t (AUC = 0.62, P = 0.05) among nonsmokers (LN stations = 75, N = 32). SUV max (AUC = 0.71, P = 0.02) was more accurate than SUV index (AUC = 0.69, P = 0.003) and SUV n/t (AUC = 0.53, P = 0.84) in predicting LN malignancy among smokers (LN stations = 95, patients = 41). However, the differences between smokers and nonsmokers for all tests were not significant (P > 0.05).
All the AUC values and 95% confidence intervals (CI), optimal cutoff values, sensitivities and specificities, and P values are listed in Table 3 . ROC curves for smokers and nonsmokers are shown 
Discussion
SUV max derived from PET/CT is the most widely used predictor of mediastinal LN malignancy in patients with lung cancer. However, the sensitivity and specificity using a cutoff value of 2.5 have varied considerably among studies. Differences may be caused by several factors, such as differences in patient populations, FDG blood levels, and tumor-and techniquespecific factors, all of which may affect the abilities of SUV max to diagnose LN malignancy accurately. We assessed the ability of SUV n/t , defined as lymph node SUV max divided by tumor SUV max , to predict LN malignancy, to eliminate the impacts of some of these factors and thus standardize SUV max . Three previous studies focused on the diagnostic accuracy of SUV n/t . [11] [12] [13] Cerfolio and Bryant [11] first confirmed SUV n/t as a potential predictor of mediastinal LN malignancy in 2007. They assessed SUV n/t in 335 FDG-avid mediastinal LNs in 239 patients, with an optimal cut-off for predicting malignancy of 0.56 (sensitivity 94%, specificity 72%) and AUC value of 0.79 (95% CI 0.66-0.88, P < 0.001). However, they did not consider the diagnostic utility of SUV max or compare it with SUV n/t . Iskender's study in 2011 produced similar results. The AUC of SUV n/t (referred to as PET predictive ratio) was 0.69 with an optimal cut-off of 0.49 for predicting malignancy (sensitivity 70%, specificity 65%). [12] However, the diagnostic utility of LN SUV max was assessed, with an optimal cutoff value 2.75 for predicting malignancy (sensitivity 84%, specificity 87%), whereas the AUC of SUV max was not mentioned or compared with the PET predictive ratio. LN SUV max was shown to be more accurate than SUV n/t for predicting LN malignancy. The diagnostic utility of SUV n/t in these 2 previous studies was similar to that found in our study, and SUV max appeared to be more accurate than SUV n/t for predicting mediastinal LN malignancy.
Mattes recently focused on the diagnostic utility of SUV n/t , [13] using a similar study design to our present study. They also selected patients with both LN SUV max values from 2.0 to 7.0 and primary tumor SUV max values >2 because it was relatively difficult to distinguish if these LNs were malignant or benign based on SUV max value alone. Mattes assessed and compared the diagnostic utilities of SUV max and SUV n/t and found that SUV n/t (AUC 0.85, 95% CI 0.78-0.92) was significantly more accurate than SUV max (AUC 0.65, 95% CI 0.55-0.76) for predicting LN malignancy. However, these results differed from those of the present study, which demonstrated that the accuracy of SUV n/t Differences in the methods used to obtain the LNs may be the most important factor contributing to the differences in results between the present and Mattes's study. All LNs in the current study were obtained by systemic LN resection, whereas most of the LNs in previous studies were obtained by mediastinoscopic biopsy or thoracotomy LN sampling. LN biopsy via mediastinoscopy or sampling may lead to potential false-negative results because the biopsied LNs may not be the positive LNs displayed in the PET/CT image. This potential false-negative rate was mentioned as a major limitation in Mattes's study. [13] Furthermore, most metastatic mediastinal LNs contain only microscopic tumor deposits, and it was therefore hard to obtain and confirm mediastinal LN tumor cells via mediastinoscopic biopsy or LN sampling. The false-negative rates of mediastinoscopic biopsy and LN sampling ranged from 4.4% to 8.2% according to previous studies.
[ [15] [16] [17] Differences between studies may also have arisen because we evaluated PET/CT-positive LNs by station, not by single positive LNs, as in all the previous studies. Furthermore, systemic LN resection guaranteed the resection of all PET/CTpositive LNs.
A third possible reason for the apparent discrepancies between study results may be the more-exclusive patient selection criteria employed in the present study. We excluded patients with GGO lung cancer because of its locally invasive characteristics and rare metastasis to LNs. [18] [19] [20] [21] We also excluded patients with multiple primary lung cancers because it was hard to confirm which tumors had caused the LN metastasis. However, unlike the previous studies, we did not exclude patients with small-cell lung Table 3 Receiver=operating characteristic curves parameters for different LN groups.
AUC (95% CI)
Cut-off Se (%) Sp (%) P cancer because we focused on the preoperative diagnostic accuracy of PET/CT, which was not limited to nonsmall cell lung cancers. It is not possible to perform preoperative lung nodule biopsies for all patients, and small-cell lung cancer patients may thus undergo surgery without pathologic confirmation, making it meaningless to limit the use of this diagnostic method to non-small cell lung cancer. Because the AUCs for SUV n/t and SUV max were not particularly informative, we hypothesized that tumor diameter may also influence the diagnostic accuracy because bigger or higher-stage tumors would have a greater possibility of LN metastasis. [22] [23] [24] We therefore assessed the diagnostic efficiency of SUV index , defined as SUV n/t multiplied by maximal tumor diameter on PET/CT. According to the results, SUV index (AUC 0.71, 95% CI 0.64-0.78) provided a better predictive index of mediastinal LN malignancy in lung cancer patients than SUV max or SUV n/t . The optimal SUV index cutoff value was 1.11, with 92.86% sensitivity and 47.18% specificity. The SUV index AUC was significantly higher than that for SUV n/t , though there was no significant difference in AUCs between SUV max (AUC = 0.67, P = 0.002) and SUV index . However, it is possible that the lack of significance was because of the limited sample size in this study.
We also evaluated the AUCs for SUV max , SUV n/t , and SUV index for predicting LN malignancy among non-smokers and smokers, respectively. Among smokers (LN station = 95, N = 41), SUV max (AUC = 0.71) was more accurate for predicting LN malignancy than and SUV n/t (AUC = 0.52) and SUV index (AUC = 0.69), whereas SUV index (AUC = 0.72) showed better diagnostic capabilities than SUV n/t (AUC = 0.69) and SUV max (AUC = 0.61) in nonsmokers. However, there were no significant differences among the 3 AUCs in either smokers or nonsmokers. It was interesting to note that the diagnostic abilities of SUV max and SUV index differed between smokers and nonsmokers, even though the differences were not statistically significant. The SUV max and SUV index ROC cutoff values in smokers were higher than in nonsmokers, indicating that malignant LNs had higher SUV max values in smokers. This may be explained by an increase in noncarcinogenic SUV max as a result of an inflammatory reaction in intrapulmonary LNs in smokers. These results suggest that it would be difficult to distinguish between inflammatory and malignant LNs on the basis of SUV max value alone. [25] [26] [27] In contrast, increases in LN SUV max in nonsmokers are less likely to be caused by an inflammatory reaction, resulting in lower SUV max values compared with smokers. However, given that there were no significant differences in AUCs for SUV max , SUV n/t , and SUV index between smokers and nonsmokers, we were unable to conclude that SUV index would be more accurate for predicting LN malignancy among nonsmokers than smokers.
All the patients in the current study underwent PET/CT and surgery in the same hospital. A lack of data from other hospitals was thus a major limitation of the present study, and we are unable to draw any conclusions about the abilities of SUV index to predict LN malignancy in other centers, or using different PET/CT scanners. Our study was also limited by the relatively small sample size, as a result of excluding many patients to avoid potential falsepositive LNs obtained by mediastinoscopic biopsy or LN sampling. Further studies conducted in more centers and with larger sample sizes are needed to confirm the accuracy of SUV index for predicting LN malignancy. Furthermore, the value of SUV max for predicting malignancy has been reported to differ between LN stations, and further studies are needed to assess the predictive accuracy for each station. [11] 
Conclusion
In conclusion, SUV index may provide a more accurate preoperative prediction of mediastinal LN malignancy in patients with lung cancer patients compared with either SUV max or SUV n/t . 
